Journal of Cardiovascular Pharmacology 1992-01-01

Antiatherosclerotic actions of isradipine.

H Sinzinger, P Fitscha

Index: J. Cardiovasc. Pharmacol. 19 Suppl 3 , S29-31, (1992)

Full Text: HTML

Abstract

Isradipine, a calcium antagonist of the dihydropyridine type, shows antiatherosclerotic actions that interfere with all three main mechanisms of atherosclerosis. These actions are mediated by the release of prostaglandin I2 and endothelium-derived relaxing factor, and the subsequent elevation of intracellular adenosine-3',5'-cyclic phosphate and 3',5'-guanosine monophosphate, respectively. These mechanisms have been proven in vitro and in animal models. Preliminary data in humans suggest that these mechanisms have clinical relevance in the long-term treatment of patients as well.

Related Compounds

  • Isradipine

Related Articles:

Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.

2014-08-01

[Brain 137(Pt 8) , 2287-302, (2014)]

Analysis of responses to the TRPV4 agonist GSK1016790A in the pulmonary vascular bed of the intact-chest rat.

2014-01-01

[Am. J. Physiol. Heart Circ. Physiol. 306(1) , H33-40, (2014)]

L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats.

2013-01-15

[Behav. Brain Res. 237 , 190-9, (2013)]

Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.

1993-04-01

[Clin. Pharm. 12(4) , 261-75, (1993)]

Experimental and clinical effects of isradipine relevant to atherosclerosis.

1994-07-01

[Am. J. Hypertens. 7(7 Pt 2) , 30S-34S, (1994)]

More Articles...